Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Abstract Introduction There is a scarcity of data beyond 1 year for the use of dupilumab to treat atopic dermatitis (AD) in a real-world setting. This study aimed to evaluate the 2-year effectiveness of dupilumab among adult and pediatric patients with moderate-to-severe AD included in a real-world,...
Main Authors: | Eric L. Simpson, Ben Lockshin, Lara Wine Lee, Zhen Chen, Moataz Daoud, Andrew Korotzer |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-01-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-01061-4 |
Similar Items
-
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01) -
Conjunctivitis as a common adverse effect of dupilumab
in atopic dermatitis
by: Mikołaj Cichoń, et al.
Published: (2023-03-01) -
Dupilumab for atopic dermatitis treatment: A single-center retrospective study
by: Gülbin Yaşar, et al.
Published: (2022-03-01) -
Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01) -
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022-05-01)